DexCom, Inc. (NASDAQ:DXCM) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of DexCom, Inc. (NASDAQ:DXCM) have been given an average rating of “Moderate Buy” by the twenty analysts that are covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $98.11.

A number of research analysts have issued reports on the company. Canaccord Genuity Group lifted their target price on DexCom from $103.00 to $106.00 and gave the company a “buy” rating in a research report on Friday, May 2nd. Piper Sandler decreased their target price on DexCom from $100.00 to $90.00 and set an “overweight” rating on the stock in a research report on Friday, May 2nd. Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and lifted their target price for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Finally, Mizuho assumed coverage on DexCom in a research report on Thursday, April 10th. They issued an “outperform” rating and a $85.00 target price on the stock.

Insider Transactions at DexCom

In related news, EVP Jereme M. Sylvain sold 7,000 shares of DexCom stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $73.83, for a total value of $516,810.00. Following the transaction, the executive vice president now directly owns 135,482 shares of the company’s stock, valued at $10,002,636.06. The trade was a 4.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the completion of the transaction, the executive vice president now directly owns 105,602 shares in the company, valued at approximately $7,432,268.76. This represents a 10.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 66,926 shares of company stock worth $4,734,384. Insiders own 0.32% of the company’s stock.

Hedge Funds Weigh In On DexCom

Several institutional investors have recently added to or reduced their stakes in DXCM. Forvis Mazars Wealth Advisors LLC increased its holdings in DexCom by 0.7% during the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company’s stock worth $1,359,000 after purchasing an additional 118 shares during the period. Principal Securities Inc. increased its holdings in DexCom by 3.4% during the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock worth $316,000 after purchasing an additional 135 shares during the period. Larson Financial Group LLC increased its holdings in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after purchasing an additional 137 shares during the period. Nia Impact Advisors LLC increased its holdings in DexCom by 1.4% during the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company’s stock worth $766,000 after purchasing an additional 140 shares during the period. Finally, Level Four Advisory Services LLC increased its holdings in DexCom by 1.1% during the 4th quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company’s stock worth $1,026,000 after purchasing an additional 150 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Up 0.4%

DXCM stock opened at $85.05 on Tuesday. The company has a market cap of $33.35 billion, a PE ratio of 59.48, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43. The business has a 50-day simple moving average of $71.14 and a 200 day simple moving average of $77.30. DexCom has a 52 week low of $57.52 and a 52 week high of $132.26. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The firm’s revenue for the quarter was up 12.5% compared to the same quarter last year. During the same period last year, the firm earned $0.32 EPS. Sell-side analysts anticipate that DexCom will post 2.03 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.